D. Singh
Univ Hosp Of South ManchesterPoster Author Of 13 e-Posters
A1116 - InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
Presenter:
Date
05/19/2019
Room
Room C141/C143/C149 (Level 1), KBHCCD
Session Name
A24 - COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS
A1277 - The Efficacy of the Combination Indacaterol/Glycopyrronium/Mometasone Furoate Is Independent of Time of Dosing in Patients with Asthma
Presenter:
Date
05/19/2019
Room
Area E (Hall F, Level 2), KBHCCD
Session Name
A31 - ASTHMA: CLINICAL STUDIES I
A1591 - COPD Assessment Test (CAT) Score Is Associated with Risk of Future Exacerbation: An Analysis from the IMPACT Trial
Presenter:
Date
05/19/2019
Room
Area B (Hall F, Level 2), KBHCCD
Session Name
A41 - COPD: EPIDEMIOLOGY
A2438 - Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial
Presenter:
Date
05/19/2019
Room
Room C141/C143/C149 (Level 1), KBHCCD
Session Name
A102 - COPD: THERAPY
A2450 - Safety and Tolerability of Four Weeks' Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III)
Presenter:
Date
05/19/2019
Room
Room C141/C143/C149 (Level 1), KBHCCD
Session Name
A102 - COPD: THERAPY
A2667 - Dupilumab Reduces Severe Exacerbations and Improves Lung Function in Late-Onset, Uncontrolled, Moderate-to-Severe Asthma Patients Enrolled in the LIBERTY ASTHMA QUEST Study
Presenter:
Date
05/20/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
B21 - SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES
A3325 - The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
Presenter:
Date
05/20/2019
Room
Area D (Hall F, Level 2), KBHCCD
Session Name
B45 - COPD: TREATMENT
A3334 - The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety
Presenter:
Date
05/20/2019
Room
Area D (Hall F, Level 2), KBHCCD
Session Name
B45 - COPD: TREATMENT
A3339 - The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
Presenter:
Date
05/20/2019
Room
Area D (Hall F, Level 2), KBHCCD
Session Name
B45 - COPD: TREATMENT
A3347 - The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings
Presenter:
Date
05/20/2019
Room
Area D (Hall F, Level 2), KBHCCD
Session Name
B45 - COPD: TREATMENT
A7081 - The Combination of Indacaterol/Glycopyrronium/Mometasone Furoate Is Superior to High-Dose Salmeterol/Fluticasone Propionate in Improving Lung Function in Patients with Asthma
Presenter:
Date
05/22/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
D101 - CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD
A7098 - Efficacy of Tiotropium/Olodaterol Compared with Tiotropium in Patients Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials
Presenter:
Date
05/22/2019
Room
Room D222-D224 (Level 2), KBHCCD
Session Name
D101 - CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD
Authors
A7344 - Reduction in the Risk of All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol Compared to Umeclidinium/Vilanterol in IMPACT Including Previously Missing or Censored Vital Status Data
Presenter:
Date
05/19/2019
Room
Room C141/C143/C149 (Level 1), KBHCCD
Session Name
A102 - COPD: THERAPY